Evidence map›Paper›PMID 34358488›Full record

SynthesisGastroenterology2021

Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.

Shailja C Shah, Adam Tepler, Cecilia P Chung, Giovanni Suarez, Richard M Peek, Adriana Hung, Christianne Roumie, Neeraj Narula

Open access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Gastric cancer prevention byFrontiers in oncology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025
    Trial
  6. Eradication rates of Helicobacter pylori regimens and predictors of treatment failure: A multicenter real-world study in Saudi Arabia.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026
    Article
  7. Phenotypic and genotypic analysis ofFrontiers in cellular and infection microbiology · 2026
    Article
  8. Article
  9. Frontiers in gastroenterology (Lausanne, Switzerland) · 2026
    Review
  10. Article
  11. Advances in the Management of RefractoryGastro hep advances · 2026
    Review
  12. Article
  13. Review
  14. Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025
    Review
  15. Article
  16. Journal of the National Cancer Center · 2024
    Review
  17. Observational
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Shailja C ShahSection of Gastroenterology, Veterans Affairs San Diego Health System, La Jolla, California; Tennessee Valley Healthcare System, Nashville, Tennessee; Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville Tennessee; Division of Gastroenterology, University of California, San Diego, La Jolla, California. Electronic address: s6shah@health.ucsd.edu.
Adam TeplerDepartment of Medicine, New York University, New York, New York.
Cecilia P ChungDivision of Rheumatology, Vanderbilt University Medical Center, Nashville, Tennessee; Section of Rheumatology, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee.
Giovanni SuarezDivision of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville Tennessee.
Richard M PeekDivision of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville Tennessee.
Adriana HungDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Section of Nephrology, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee.
Christianne RoumieDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Veterans Affairs, Medical Service and Geriatric Research and Education Clinical Center, Tennessee Valley Healthcare System, Nashville, Tennessee.
Neeraj NarulaDivision of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
VA Tennessee Valley Healthcare System · USVanderbilt University Medical Center · USNew York University · USPopulation Health Research Institute · CAUC San Diego Health System · US

Funding

Role of Iron and B-Catenin Activation in Gastric CarcinogenesisP01CA116087 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TIMOTHY L COVER · 2009 to 2026
$27.5M
H.Pylori Relationship to Digestive Diseases and CancerR01CA077955 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2003 to 2026
$9.7M
Helicobacter Pylori and Gastrointestinal BiologyR01DK058587 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEK, RICHARD M. · 2001 to 2024
$7.8M
Learning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7M
Optimization of Helicobacter pylori-related Disease Outcomes in VeteransIK2CX002027 · VA · VETERANS HEALTH ADMINISTRATION · PI SHAILJA C SHAH · 2020 to 2026
–
AHRQ HHS K12 HS026395CSRD VA IK2 CX002027NCI NIH HHS P01 CA116087NCI NIH HHS R01 CA077955NIDDK NIH HHS R01 DK058587
6 · The paper itself

Abstract

BACKGROUND &

aimsHelicobacter pylori infects approximately 50% of individuals worldwide. Successful H pylori eradication is associated with reduced risk of gastric cancer and peptic ulcer disease, among other conditions. We hypothesized that host genetic determinants, especially those affecting gastric pH, might contribute to eradication therapy failure, particularly when treatment adherence and antibiotic susceptibility are confirmed. We aimed to conduct a meta-analysis of host genetic variants associated with H pylori eradication failure.

methodsWe searched the literature for studies comparing posttreatment H pylori eradication failure vs success (outcome) according to host genetic polymorphisms (exposure). Reference groups were defined according to genotypes (or corresponding phenotypes) hypothesized to be associated with successful eradication. We pooled estimates using a random-effects model and performed comprehensive sensitivity analyses.

resultsWe analyzed 57 studies from 11 countries; the vast majority analyzed CYP2C19 polymorphisms. Among individuals prescribed eradication regimens with proton pump inhibitors predominantly CYP2C19 metabolized, enhanced vs poor metabolizer phenotypes were associated with a 2.52-fold significantly higher likelihood of eradication failure and 4.44-fold significantly higher likelihood when treatment adherence and H pylori clarithromycin susceptibility (if relevant) were confirmed. There was no association between CYP2C19 variants and eradication failure if proton pump inhibitors less metabolized by or that bypass CYP2C19 metabolism were used. IL1B polymorphisms that are vs are not associated with less gastric acid suppression were associated with 1.72-fold significantly higher likelihood of eradication failure. There was no association between MDR1 polymorphisms and H pylori eradication failure. The certainty of evidence was moderate.

conclusionBased on meta-analysis, we identified host genetic polymorphisms significantly associated with H pylori eradication failure; host genetics might underlie eradication failure among treatment-adherent individuals with confirmed H pylori antibiotic susceptibility.

Indexed as

Pharmacogenomic VariantsPolymorphism, Single NucleotideAdultAgedAged, 80 and overAnti-Bacterial AgentsATP Binding Cassette Transporter, Subfamily BCytochrome P-450 CYP2C19Drug Resistance, BacterialFemaleHelicobacter InfectionsHelicobacter pyloriHumansInterleukin-1betaMaleMiddle AgedABCB1 protein, humanAnti-Bacterial AgentsATP Binding Cassette Transporter, Subfamily BCYP2C19 protein, humanCytochrome P-450 CYP2C19IL1B protein, humanInterleukin-1betaProton Pump InhibitorsAntibiotic ResistanceGenome-Wide Association StudiesPharmacogeneticsPrecision MedicineStomach Neoplasm

Identifiers

PMID34358488
PMCPMC8545829
OpenAlexW3190820567

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.